Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON, January 3 /PRNewswire/ --

- Higher Paycheques, Flexible Work Arrangements, Candidate Screening Online Among Major Trends for 2008 -

CareerBuilder.co.uk, a leading job site in the UK, released the results of its annual job forecast, conducted by Harris Interactive(R), tracking projected hiring and job search activities for the upcoming quarter and 2008. The survey, titled "2008 UK Job Forecast" was conducted between November 14 and December 3, 2007 and included 281 hiring managers and human resource professionals and 507 workers.

CALGARY, Canada, January 3 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).

LYON, France, January 3 /PRNewswire/ --

- Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. (Euronext, NASDAQ: CRXL) for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

BEVERLY HILLS, California, January 3 /PRNewswire/ --

Pop singer Alisa Apps shuns the idea of signing with major record label and decides to go her own way. Apps, who just launched her website and singing career 10 days ago, announced that she is not seeking to be signed with a major record label.

Her fantastically successful YouTube campaign started 10 days ago and has fans raving.

Alisa started with "Will somebody PLEASE sing Jingle Bells with me???" Within 2 days she had 90,000+ views.

CHICAGO, January 3 /PRNewswire/ --

- Global conferencing leader aligns with Sustainable Development International and United Nations Environment Program for worldwide communications initiative

InterCall, the world's largest conferencing provider, is now a Platinum sponsor of Climate Action, a joint development of Sustainable Development International and the United Nations Environment Program (UNEP) promoting environmentally-responsible business.

WILMINGTON, North Carolina, January 2 /PRNewswire/ --

- Strengthens global leadership in drug development

PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Sebastian Pacios, M.D., as senior vice president of clinical operations for Europe, Middle East and Africa (EMEA). In this role, Dr. Pacios will oversee Phase II-IV clinical development for PPD's operations in these geographic regions.